Akari Therapeutics (AKTX)
NASDAQ:AKTX
Want to see AKTX full AI Analyst Report?
Top Page
Akari Therapeutics
(NASDAQ:AKTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▲(1507.14% Upside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn) and a strongly bearish technical setup (price well below major moving averages with negative MACD). Capital-related corporate actions are a modest positive, but valuation support is limited given negative earnings and no dividend.
Positive Factors
Improved Balance Sheet
Low leverage and a restored equity position reduce near-term solvency pressure versus prior negative equity. This structural balance sheet improvement increases flexibility to fund R&D and lowers immediate refinancing risk over the coming months.
Negative Factors
No Revenue Base
The absence of any operating revenue means the business cannot generate internal margins or earnings. Long-term viability is highly contingent on clinical or regulatory success or continual capital raises, making outcomes binary and raising structural risk for funding continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Low leverage and a restored equity position reduce near-term solvency pressure versus prior negative equity. This structural balance sheet improvement increases flexibility to fund R&D and lowers immediate refinancing risk over the coming months.
Read all positive factors
Akari Therapeutics (AKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.22M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.99
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.01
Forecast
1Y Price Target
$27.00Price Target Upside9542.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.89
Revenue Forecast (FY)N/A
Akari Therapeutics Business Overview & Revenue Model
Company Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents...
How the Company Makes Money
null...
Akari Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.35M | -19.53M | -16.80M | -23.08M | -17.21M |
| Net Income | -17.30M | -19.79M | -10.01M | -17.75M | -17.42M |
Balance Sheet | |||||
| Total Assets | 47.89M | 50.56M | 4.36M | 13.83M | 11.65M |
| Cash, Cash Equivalents and Short-Term Investments | 5.20M | 2.60M | 3.85M | 13.25M | 9.36M |
| Total Debt | 754.00K | 3.26M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 19.56M | 28.33M | 4.58M | 12.04M | 6.09M |
| Stockholders Equity | 28.33M | 22.23M | -229.00K | 1.79M | 5.55M |
Cash Flow | |||||
| Free Cash Flow | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Operating Cash Flow | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Investing Cash Flow | 0.00 | 382.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 13.17M | 10.99M | 7.02M | 25.29M | 14.29M |
Akari Therapeutics Technical Analysis
Negative
0.28
Price Trends
7.81
Negative
10.35
Negative
23.38
Negative
Market Momentum
-1.20
Negative
37.04
Neutral
42.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 5.02, below the 50-day MA of 7.81, and below the 200-day MA of 23.38, indicating a bearish trend. The MACD of -1.20 indicates Negative momentum. The RSI at 37.04 is Neutral, neither overbought nor oversold. The STOCH value of 42.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.
Akari Therapeutics Risk Analysis
Akari Therapeutics disclosed 61 risk factors in its most recent earnings report. Akari Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Akari Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $38.14M | -0.72 | -87.18% | ― | ― | 38.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $206.35M | 5.44 | -21.16% | ― | -92.42% | 62.37% | |
45 Neutral | $25.27M | -2.53 | -94.03% | ― | ― | 32.92% | |
44 Neutral | $13.02M | -1.17 | ― | ― | ― | 79.31% | |
42 Neutral | $5.22M | -0.56 | -68.21% | ― | ― | ― |
* Healthcare Sector Average
AKTX
Akari Therapeutics
4.61
-39.39
-89.52%
NNVC
NanoViricides
1.17
-0.23
-16.43%
MBRX
Moleculin Biotech
2.44
-20.54
-89.38%
PASG
Passage Bio
11.89
5.31
80.70%
SABS
SAB Biotherapeutics
4.05
2.66
191.37%
Akari Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Akari Therapeutics Announces ADS Ratio Change, Reverse Split
Neutral
Mar 17, 2026
On March 17, 2026, Akari Therapeutics announced it will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares, effective around March 31...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Akari Shareholders Approve Warrant Exercises and Share Issuances
Positive
Mar 2, 2026
On March 2, 2026, Akari Therapeutics held a special general meeting of shareholders at which a quorum was present and all resolutions were approved, covering the exercisability and share issuance related to multiple warrant classes tied to recent ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.